Cargando…

Role of MicroRNA Modulation in the Interferon-α/Ribavirin Suppression of HIV-1 In Vivo

BACKGROUND: Interferon-α (IFN-α) treatment suppresses HIV-1 viremia and reduces the size of the HIV-1 latent reservoir. Therefore, investigation of the molecular and immunologic effects of IFN-α may provide insights that contribute to the development of novel prophylactic, therapeutic and curative s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abdel-Mohsen, Mohamed, Deng, Xutao, Danesh, Ali, Liegler, Teri, Jacobs, Evan S., Rauch, Andri, Ledergerber, Bruno, Norris, Philip J., Günthard, Huldrych F., Wong, Joseph K., Pillai, Satish K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183579/ https://www.ncbi.nlm.nih.gov/pubmed/25275557 http://dx.doi.org/10.1371/journal.pone.0109220

Ejemplares similares

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study
por: Kovari, Helen, et al.
Publicado: (2015)

Expression profile of host restriction factors in HIV-1 elite controllers
por: Abdel-Mohsen, Mohamed, et al.
Publicado: (2013)

Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure
por: Sendi, Pedram, et al.
Publicado: (2007)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Granulocyte-Derived Extracellular Vesicles Activate Monocytes and Are Associated With Mortality in Intensive Care Unit Patients
por: Danesh, Ali, et al.
Publicado: (2018)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection
por: Fitzmaurice, Karen, et al.
Publicado: (2015)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis
por: Grant, Robert M., et al.
Publicado: (2015)

Host and Viral Genetic Correlates of Clinical Definitions of HIV-1 Disease Progression
por: Casado, Concepción, et al.
Publicado: (2010)

Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens
por: Younossi, Zobair M., et al.
Publicado: (2016)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]
por: Veldt, Bart J, et al.
Publicado: (2003)

Disentangling Human Tolerance and Resistance Against HIV
por: Regoes, Roland R., et al.
Publicado: (2014)

Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha, and ribavirin plus lopinavir/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol
por: Zeng, Yan-Ming, et al.
Publicado: (2020)

Thyroid hormonal disturbances related to treatment of hepatitis C with interferon-alpha and ribavirin
por: Danilovic, Debora Lucia Seguro, et al.
Publicado: (2011)

354 Autoimmune Hepatitis Misdiagnosed as Hepatitis C Responding to Interferon/Ribavirine Therapy
por: Pijak, Michal R., et al.
Publicado: (2012)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection
por: Shimojima, Masayuki, et al.
Publicado: (2015)

MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin
por: Yen, Yi-Hao, et al.
Publicado: (2016)

Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country
por: Hlaing, Naomi Khaing Than, et al.
Publicado: (2016)

Molecular Analyses Define Vα7.2-Jα33+ MAIT Cell Depletion in HIV Infection: A Case–Control Study
por: Ussher, James E., et al.
Publicado: (2015)

Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection
por: Begré, Lorin, et al.
Publicado: (2022)

T-Cell Exhaustion in HIV-1/Hepatitis C Virus Coinfection Is Reduced After Successful Treatment of Chronic Hepatitis C
por: Caraballo Cortés, Kamila, et al.
Publicado: (2023)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

A CD4(+) T cell antagonist epitope down-regulates activating signaling proteins, up-regulates inhibitory signaling proteins and abrogates HIV-specific T cell function
por: Jacobs, Evan S, et al.
Publicado: (2014)

Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis
por: Ahmed, Mohammed Mahmound, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ns064vm5f7lbiojb26pelsbu48